Abstract
Cardiovascular-related morbidity and mortality in patients with peripheral arterial obstructive disease remain high. We performed an international, multicenter, randomized, double-blind, placebo-controlled trial to investigate whether long-term administration of oral buflomedil could reduce the rate of cardiovascular events in patients with intermittent claudication. Patients >40 years of age with documented peripheral arterial obstructive disease, intermittent claudication, and an ankle-brachial index between 0.30 and 0.80 were eligible for inclusion and were randomized to receive orally either buflomedil or placebo for 2 to 4 years. Aspirin was recommended for all patients (unless they were receiving other antithrombotic treatments at inclusion). The primary efficacy outcome was critical cardiovascular events, defined as the composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, symptomatic deterioration of peripheral arterial obstructive disease, or leg amputation. A total of 2078 patients were recruited. Mean treatment duration was 33 months. The rate of critical cardiovascular events was significantly lower in buflomedil-randomized patients than in placebo-randomized patients (9.1% versus 12.4%...Continue Reading
References
Jan 1, 1987·Current Medical Research and Opinion·A PlataniaG De Martino Rosaroll
Oct 1, 1981·Angiology·A Dubourg, R F Scamuffa
Sep 1, 1994·International Journal of Microcirculation, Clinical and Experimental·M D MengerK Messmer
Nov 16, 1996·Lancet·UNKNOWN CAPRIE Steering Committee
Dec 5, 1998·Shock·K HolzerK Messmer
Jan 20, 2000·The New England Journal of Medicine·UNKNOWN Heart Outcomes Prevention Evaluation Study InvestigatorsG Dagenais
Jan 12, 2002·BMJ : British Medical Journal·UNKNOWN Antithrombotic Trialists' Collaboration
Jan 25, 2002·Current Controlled Trials in Cardiovascular Medicine·Thomas W Meade, UNKNOWN For the British Medical Research Council General Practice Research Framework and participating vascular clinics
Jan 29, 2002·The American Journal of Medicine·Judith G Regensteiner, William R Hiatt
Nov 16, 2002·BMJ : British Medical Journal·Tom MeadeJackie Cooper
May 28, 2003·Journal of the American College of Cardiology·Emile R MohlerAlan T Hirsch
Sep 4, 2003·Circulation·Emile R MohlerMark A Creager
Sep 16, 2003·The American Journal of Cardiology·Wilbert S AronowChul Ahn
May 10, 2005·Arteriosclerosis, Thrombosis, and Vascular Biology·Anand V Doobay, Sonia S Anand
Oct 11, 2005·Lancet·C BaigentUNKNOWN Cholesterol Treatment Trialists' (CTT) Collaborators
Jan 31, 2006·American Heart Journal·Maurizio MangiavacchiEdoardo Gronda
Feb 2, 2006·JAMA : the Journal of the American Medical Association·Graeme J HankeyJohn W Eikelboom
Mar 22, 2006·Circulation·Alan T HirschUNKNOWN Vascular Disease Foundation
Jan 16, 2007·Journal of Vascular Surgery·L NorgrenUNKNOWN TASC II Working Group
Mar 22, 2007·JAMA : the Journal of the American Medical Association·Ph Gabriel StegUNKNOWN REACH Registry Investigators
Citations
Aug 30, 2011·European Heart Journal·UNKNOWN European Stroke OrganisationUNKNOWN ESC Committee for Practice Guidelines
Aug 29, 2009·Journal des maladies vasculaires·A LongA Hadj Henni
Feb 13, 2008·Circulation·Michael S Conte
Jun 17, 2009·Expert Opinion on Pharmacotherapy·Andrew B McCann, Michael R Jaff
Sep 4, 2008·Circulation·Tine L De BackerLuc M Van Bortel
Jul 31, 2008·Current Medical Research and Opinion·Emile MohlerUNKNOWN AHA
Apr 29, 2009·Pharmacotherapy·Paul P DobeshEmily L Persson
Apr 25, 2009·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Tine L M De BackerLuc M Van Bortel
Apr 2, 2013·The Cochrane Database of Systematic Reviews·Tine L M de Backer, Robert Vander Stichele